Tag Archive for: Domain Therapeutics

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases

/in

DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with potential to directly impact inflammation, tissue damage, and pain  Strasbourg, France – Montreal, Canada – Boston, United States, March 20, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts […]

Read more

Domain Therapeutics to present and participate at major global healthcare conferences, March to June 2025

/in

Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for […]

Read more